服用芳香化酶抑制剂的患者注意事项。
Precautions for Patients Taking Aromatase Inhibitors.
作者信息
Heery Mary, Farley Stephen, Sparkman Rhett, Healy John, Eighmy William, Zahrah George, Zelkowitz Richard
机构信息
Western Connecticut Health Network at The Smilow Family Breast Health Center, Norwalk Hospital, Norwalk, Connecticut.
Whittingham Cancer Center, Norwalk Hospital, Norwalk, Connecticut.
出版信息
J Adv Pract Oncol. 2020 Mar;11(2):184-189. doi: 10.6004/jadpro.2020.11.2.6. Epub 2020 Mar 1.
Abstract
Aromatase inhibitors are the drug of choice for the treatment of estrogen receptor- or progesterone receptor-positive breast cancer in postmenopausal women. Aromatase is an enzyme that catalyzes the final and rate-limiting step in the biosynthesis of estrogen. Inhibitors of this enzyme are an effective therapy for breast cancer. The benefits of these agents have been clearly shown through various clinical trials, yet adherence may be challenging for some patients due to issues of drug interactions, proper first dose education, and adverse effects. Education to prevent and treat adverse effects is of the utmost importance to promote adherence.
摘要
芳香化酶抑制剂是治疗绝经后女性雌激素受体或孕激素受体阳性乳腺癌的首选药物。芳香化酶是一种催化雌激素生物合成的最后一步且限速步骤的酶。这种酶的抑制剂是乳腺癌的一种有效治疗方法。通过各种临床试验已清楚表明了这些药物的益处，但由于药物相互作用、正确的首剂教育以及不良反应等问题，对一些患者而言坚持用药可能具有挑战性。预防和治疗不良反应的教育对于促进坚持用药至关重要。
相似文献
1
Precautions for Patients Taking Aromatase Inhibitors.服用芳香化酶抑制剂的患者注意事项。
J Adv Pract Oncol. 2020 Mar;11(2):184-189. doi: 10.6004/jadpro.2020.11.2.6. Epub 2020 Mar 1.
2
Molecular Action and Clinical Relevance of Aromatase Inhibitors.芳香化酶抑制剂的分子作用及临床相关性
Oncologist. 1998;3(2):129-130.
3
Role of aromatase inhibitors in the treatment of breast cancer.芳香化酶抑制剂在乳腺癌治疗中的作用。
Clin Ther. 2004 Aug;26(8):1199-214. doi: 10.1016/s0149-2918(04)80017-1.
4
Are all aromatase inhibitors the same? A review of the current evidence.所有芳香化酶抑制剂都一样吗？当前证据综述。
Breast. 2004 Dec;13 Suppl 1:S10-8. doi: 10.1016/j.breast.2004.09.003.
5
Aromatase inhibitors as potential cancer chemopreventives.芳香化酶抑制剂作为潜在的癌症化学预防剂。
Cancer Epidemiol Biomarkers Prev. 1998 Jan;7(1):65-78.
6
The evolving role of aromatase inhibitors in breast cancer.芳香化酶抑制剂在乳腺癌中不断演变的作用。
Int J Clin Oncol. 2002 Oct;7(5):279-83. doi: 10.1007/s101470200040.
7
Aromatase, aromatase inhibitors, and breast cancer.芳香酶、芳香酶抑制剂与乳腺癌。
J Steroid Biochem Mol Biol. 2011 May;125(1-2):13-22. doi: 10.1016/j.jsbmb.2011.02.001. Epub 2011 Feb 16.
8
Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.氟维司群治疗激素受体阳性晚期乳腺癌绝经后患者的疗效和安全性：系统文献回顾和荟萃分析。
Breast Cancer Res Treat. 2018 Oct;171(3):535-544. doi: 10.1007/s10549-018-4867-y. Epub 2018 Jul 4.
9
Focus on anastrozole and breast cancer.关注阿那曲唑与乳腺癌。
Curr Med Res Opin. 2003;19(8):683-8. doi: 10.1185/030079903125002397.
10
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.美国临床肿瘤学会关于芳香化酶抑制剂作为激素受体阳性绝经后乳腺癌妇女辅助治疗的技术评估：2004年现状报告
J Clin Oncol. 2005 Jan 20;23(3):619-29. doi: 10.1200/JCO.2005.09.121. Epub 2004 Nov 15.
引用本文的文献
1
Determination and Disposition of the Aromatase Inhibitor Exemestane in CYP3A-Deficient Mice.CYP3A基因缺陷小鼠中芳香化酶抑制剂依西美坦的测定与处置
Molecules. 2025 Mar 24;30(7):1440. doi: 10.3390/molecules30071440.
2
Effects of a Multimodal Program on Frailty Syndrome and Psychological Alterations in Breast Cancer Women Treated with Aromatase Inhibitors.多模式方案对接受芳香化酶抑制剂治疗的乳腺癌女性虚弱综合征及心理改变的影响。
Clin Pract. 2025 Feb 21;15(3):41. doi: 10.3390/clinpract15030041.
3
A researcher's guide to studying sex differences in immune aging.研究免疫衰老中性别差异的研究者指南。
Trends Mol Med. 2025 Jan 29. doi: 10.1016/j.molmed.2025.01.005.
4
Mind the Gap: Unraveling the Intricate Dance Between Alzheimer's Disease and Related Dementias and Bone Health.注意差距：揭开阿尔茨海默病及相关痴呆症与骨骼健康之间错综复杂的关系。
Curr Osteoporos Rep. 2024 Feb;22(1):165-176. doi: 10.1007/s11914-023-00847-x. Epub 2024 Jan 29.
5
Precautions for Patients Taking Tamoxifen or Aromatase Inhibitors.服用他莫昔芬或芳香化酶抑制剂的患者注意事项。
J Adv Pract Oncol. 2023 Sep;14(6):478-482. doi: 10.6004/jadpro.2023.14.6.2. Epub 2023 Sep 1.
6
Role of the pharmacist in the management of postmenopausal breast cancer treatment with vasomotor symptoms: A case report.药剂师在绝经后乳腺癌伴血管舒缩症状治疗管理中的作用：病例报告
Explor Res Clin Soc Pharm. 2023 Aug 24;11:100324. doi: 10.1016/j.rcsop.2023.100324. eCollection 2023 Sep.
本文引用的文献
1
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.MONARCH 3最终无进展生存期：阿贝西利作为晚期乳腺癌初始治疗的随机研究。
NPJ Breast Cancer. 2019 Jan 17;5:5. doi: 10.1038/s41523-018-0097-z. eCollection 2019.
2
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.激素受体阳性乳腺癌妇女的辅助内分泌治疗：ASCO 临床实践指南更新焦点。
J Clin Oncol. 2019 Feb 10;37(5):423-438. doi: 10.1200/JCO.18.01160. Epub 2018 Nov 19.
3
Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.针刺与假针刺或等待对照治疗早期乳腺癌妇女芳香化酶抑制剂相关关节痛的效果：一项随机临床试验。
JAMA. 2018 Jul 10;320(2):167-176. doi: 10.1001/jama.2018.8907.
4
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.绝经前乳腺癌的辅助内分泌治疗。
N Engl J Med. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4.
5
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.MONALEESA-3：来曲唑和氟维司群治疗激素受体阳性、人表皮生长因子受体 2 阴性晚期乳腺癌的 III 期随机研究。
J Clin Oncol. 2018 Aug 20;36(24):2465-2472. doi: 10.1200/JCO.2018.78.9909. Epub 2018 Jun 3.
6
Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.随机维生素 D3 试验预防接受辅助来曲唑治疗的乳腺癌女性肌肉骨骼症状恶化。VITAL 试验。
Breast Cancer Res Treat. 2017 Nov;166(2):491-500. doi: 10.1007/s10549-017-4429-8. Epub 2017 Aug 2.
7
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.辅助他莫昔芬和依西美坦用于绝经后早期乳腺癌女性（TEAM）：一项多中心、开放标签、随机、3 期临床试验的 10 年随访。
Lancet Oncol. 2017 Sep;18(9):1211-1220. doi: 10.1016/S1470-2045(17)30419-9. Epub 2017 Jul 18.
8
Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.接受芳香化酶抑制剂治疗早期乳腺癌的女性中，阴道用睾酮乳膏与雌二醇阴道环治疗阴道干燥或性欲降低的随机临床试验。
JAMA Oncol. 2017 Mar 1;3(3):313-319. doi: 10.1001/jamaoncol.2016.3904.
9
Extra-gonadal sites of estrogen biosynthesis and function.雌激素生物合成与功能的性腺外部位。
BMB Rep. 2016 Sep;49(9):488-96. doi: 10.5483/bmbrep.2016.49.9.141.
10
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.将芳香化酶抑制剂辅助治疗延长至10年。
N Engl J Med. 2016 Jul 21;375(3):209-19. doi: 10.1056/NEJMoa1604700. Epub 2016 Jun 5.
Zotero 插件